Headlines about Cleveland BioLabs (NASDAQ:CBLI) have been trending somewhat positive this week, Accern reports. Accern ranks the sentiment of news coverage by analyzing more than twenty million blog and news sources in real-time. Accern ranks coverage of publicly-traded companies on a scale of negative one to one, with scores nearest to one being the most favorable. Cleveland BioLabs earned a media sentiment score of 0.18 on Accern’s scale. Accern also assigned news coverage about the biotechnology company an impact score of 44.3016093085546 out of 100, indicating that recent news coverage is somewhat unlikely to have an effect on the company’s share price in the immediate future.
Cleveland BioLabs (CBLI) traded down $0.30 during midday trading on Monday, hitting $3.80. 59,100 shares of the company traded hands, compared to its average volume of 389,562. The company has a market cap of $39.73, a P/E ratio of -4.32 and a beta of -0.32. Cleveland BioLabs has a fifty-two week low of $1.22 and a fifty-two week high of $5.55.
Cleveland BioLabs (NASDAQ:CBLI) last posted its quarterly earnings data on Tuesday, November 14th. The biotechnology company reported ($0.11) earnings per share (EPS) for the quarter. The firm had revenue of $0.30 million for the quarter. Cleveland BioLabs had a negative return on equity of 91.87% and a negative net margin of 472.44%.
TRADEMARK VIOLATION NOTICE: “Cleveland BioLabs (CBLI) Receives Daily News Impact Score of 0.18” was first posted by Week Herald and is owned by of Week Herald. If you are reading this story on another site, it was copied illegally and reposted in violation of U.S. & international trademark and copyright law. The original version of this story can be viewed at https://weekherald.com/2017/12/25/cleveland-biolabs-cbli-receives-daily-news-impact-score-of-0-18-2.html.
Cleveland BioLabs Company Profile
Cleveland BioLabs, Inc (CBLI) is a biopharmaceutical company. The Company is engaged in developing approaches to activate the immune system and address serious medical needs. Its platform of Toll-like immune receptor activators has applications in mitigation of radiation injury and immuno-oncology. Its advanced product candidate is Entolimod, an immuno-stimulatory agent, which it is developing as a radiation countermeasure and an immunotherapy for oncology and other indications.
Receive News & Ratings for Cleveland BioLabs Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Cleveland BioLabs and related companies with MarketBeat.com's FREE daily email newsletter.